Advertisement

Topics

Companies Related to "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" [Most Relevant Company Matches] RSS

10:01 EST 21st November 2018 | BioPortfolio

Here are the most relevant search results for "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" found in our extensive corporate database of over 50,000 company records.

Showing "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" Companies 1–25 of 3,700+

Relevant

Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris) is a publicly traded, fully integrated pharmaceutical company [002294:CH]. Founded in 1998, Salubris has grown to achieve sales of >$750M USD in 2017. Salubris is headquartered in Shenzhen, China, and has over 3,800 employees working across R&D, regulatory, marketing and sales. Its marketed products in...


Intec Pharma Ltd.

Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and s...

Landscape Structures

Since 1971, Landscape Structures Inc. has been the leading commercial playground equipment manufacturer in the world. The only major playground equipment company that is employee-owned, Landscape Structures encourages outdoor play that develops healthy kids and a sustainable world by creating innovative products that are environmentally responsible. The company's mission from day one has been to e...


PolyMedix

PolyMedix is the leader in developing biomimetics - novel small molecule, oligomer and polymer protein-mimetic drugs for membrane protein and protein:protein targets. PolyMedix has a proven computational technology platform which was used to develop its first program: a line of unique anti-infective drugs for which bacterial resistance is highly unlikely to develop. Proteins are the machinery of ...

DeuteRx, LLC

DeuteRx has pioneered ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. The development of the single, preferred enantiomer from the parent...

Synthetic Turf Council

Based in Atlanta, the Synthetic Turf Council was founded in 2003 to promote the industry and to assist buyers and end users with the selection, use and maintenance of synthetic turf systems in sports field, golf, municipal parks, airports, landscape and residential applications. The organization is also a resource for current, credible, and independent research on the safety and environmental imp...

DeuteRx LLC

DeuteRx is pioneering ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. Numerous drugs are still developed and marketed as racemic mixtures...

FortuneRock (China) Ltd.

FortuneRock (China) Ltd., a privately held biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 wholly owned subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombina...

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

American Society of Landscape Architects (ASLA)

Founded in 1899, the American Society of Landscape Architects (ASLA) is the national professional association for landscape architects, representing more than 15,000 members in 49 professional chapters and 76 student chapters. The Society's mission is to lead, to educate, and to participate in the careful stewardship, wise planning, and artful design of ou...

Gene Network Sciences

Gene Network Sciences (GNS) is a privately held biosimulation company with offices in Ithaca, New York, and Cambridge, Massachusetts. Founded in 2000, GNS creates data-driven compound simulation models that help pharmaceutical companies improve the quality of their drug candidates. Leading the company's multi-disciplinary approach are scientists specializing in molecular biology, computer science,...

Lupin Pharmaceuticals, Inc

Lupin is one of the world's largest manufacturers of drugs that combat tuberculosis,bacterial infections,and cardiovascular disease.Our portfolio of drugs, manufactured in global-scale USFDA and UKMCA approved plants,also includes NSAIDS,Cox2 inhibitors and herbal-based phytomedicines.

FortuneRock (China) Co., Ltd.

FortuneRock (China) Co., Ltd., a biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombinant protein drugs with h...

Prosidion Ltd

(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Ph...

AWAKENS, Inc.

AWAKENS is a genomic software company transforming the landscape of consumer genomics. They empower consumers with easily accessible insights of their own genome data, and diversify consumer genomics services by providing an API toolkit for existing services to provide personalized solutions tailored to each person’s genetic makeup. Founded in January...

bioRASI

bioRASI is a full service global CRO providing optimized pipeline development TM. This strategic initiative of the Russian Academy of Sciences conducts research throughout the Americas, Europe, and Asia, and is experienced in biologicals, medical devices, and small drugs, maintaining equal balance between Pilot, Phase I/BE, and Phase II/IV studies.

Tosk Inc.

Tosk was founded in 1998 to discover new drugs for genetic diseases and cancer. The original technology, in part licensed from Stanford University,StealthGene and Targeted Gene Delivery technologies. In the process, Tosk discovered and perfected the Optimizing Marketed Drugs side-effect-reducing drugs.Tosk's current drug discovery and development efforts focus on applying the OMD approach to disco...

InSite Vision Inc.

InSite Vision is advancing new specialty ophthalmic products for the treatment of diseases affecting the front and back of the eye. The company has two commercial products based on its innovative DuraSite® platform approved for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn, In...

Spectrum Pharmaceuticals Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs and has an advanced stage pipeline that has the potential to transform the company. Spectrum's strong track record for in-l...

NAM Asia Hong Kong Co., Ltd.

CEO Teppei Nakano graduated from Keio University School of Medicine in 2017. We have been adopting IPA unexplored projects by the Ministry of Economy, Trade and Industry, which represent a large number of representatives of IT companies representing Japan, twice in 2016 and 2017, independent businesses that have been adopted by unexplored This is the NAM p...

Calvert Laboratories, Inc.

We excel in the design and submission of preclinical development programs to various regulatory agencies (FDA, EPA, EEC, OECD, MHW) located all over the world. We are experienced in virtually all classes of compounds. We offer capabilities in the performance of studies to support the safety evaluation of drugs, chemicals and some devices from not only the discovery phase but through the preclinica...

MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription an...

Marshall Edwards

Marshall Edwards, Inc. ('MEI') is a pharmaceutical company dedicated to the field of cancer therapy (oncology).MEI is developing a range of anti-cancer therapies that represents the next generation of oncology drugs - multiple signal transduction regulators (abbreviated as 'MSTRs') that reach to the heart of the cancer process.The source of this new range of drugs is a family of chemicals, discove...

Axaron Bioscience AG

Axaron Bioscience AG is a biotech company that aims to develop drugs which address the large-volume and fast growing neurodegenerative disorders market. The company has built an attractive portfolio of compounds focused on the treatment of stroke, Spinal Cord Injury (SCI), ALS (Amyotrophic Lateral Sclerosis) and Parkinson's disease. The most advanced drug candidate AX200 has already entered phase ...


More From BioPortfolio on "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks